HK Stock Market Move | PEIJIA-B (09996) rose over 5%, with a revenue increase of up to 23% in the first half of the year. TaurusTrio has been implanted over 660 cases in the mainland.

PEIJIA-B (09996) has risen over 5%, and as of the time of writing, it is up 4.75%, priced at HKD 5.29, with a transaction volume of HKD 2.8668 million. In terms of news, Peijia Medical recently disclosed that its revenue for the first half of this year is approximately RMB 415 million to RMB 435 million, representing a year-on-year growth of about 17.4% to 23.1%. This growth is primarily attributed to the continuous expansion of its transcatheter valve treatment business, driven by the successful commercialization of new indication products; the neurointerventional business continues to grow under the penetration of self-developed products and strategic collaborations. During the reporting period, a total of approximately 2,830 TAVR (Transcatheter Aortic Valve Replacement) implants were performed, showing a significant increase of about 36.5% compared to the same period last year, with hospital coverage expanding to over 850 in Greater China; the TaurusTrio specifically designed for aortic regurgitation (AR) has completed commercialization, with over 660 implants in mainland China, demonstrating good clinical acceptance and commercialization potential.